STEMPOINT CAPITAL LP

13D and 13G Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
Xilio Therapeutics, Inc. 13G/A Amendment 2 XLO · 98422T209	XLO	98422T209	9.5%	628,866	13G/A Amendment 2	8/14/2026 Event 6/30/2026
StemPoint Capital LP			9.5%	628,866
StemPoint Capital Management GP LLC			9.5%	628,866
Michelle Ross			9.5%	628,866
Surrozen, Inc. 13G SRZN · 86889P208	SRZN	86889P208	5.0%	602,798	13G	8/14/2026 Event 6/30/2026
StemPoint Capital LP			5.0%	602,798
StemPoint Capital Management GP LLC			5.0%	602,798
Michelle Ross			5.0%	602,798
Faeth Therapeutics, Inc. 13G/A Amendment 1 FTH · 81728A207	FTH	81728A207	0%	0	13G/A Amendment 1	8/14/2026 Event 6/30/2026
StemPoint Capital LP			0%	0
StemPoint Capital Management GP LLC			0%	0
Michelle Ross			0%	0
Cellectar Biosciences, Inc. 13G CLRB · 15117F880	CLRB	15117F880	9.9%	845,740	13G	8/14/2026 Event 6/30/2026
StemPoint Capital LP			9.9%	845,740
StemPoint Capital Management GP LLC			9.9%	845,740
Michelle Ross			9.9%	845,740
Surrozen, Inc. 13G/A Amendment 5 SRZN · 86889P208	SRZN	86889P208	4.5%	525,639	13G/A Amendment 5	5/15/2026 Event 3/31/2026
StemPoint Capital LP			4.5%	525,639
StemPoint Capital Management GP LLC			4.5%	525,639
Michelle Ross			4.5%	525,639
Sensei Biotherapeutics, Inc. 13G FTH · 81728A207	FTH	81728A207	9.9%	132,873	13G	5/15/2026 Event 3/31/2026
StemPoint Capital LP			9.9%	132,873
StemPoint Capital Management GP LLC			9.9%	132,873
Michelle Ross			9.9%	132,873
Vistagen Therapeutics, Inc. 13G/A Amendment 2 VTGN · 92840H400	VTGN	92840H400	1.5%	616,749	13G/A Amendment 2	2/17/2026 Event 12/31/2025
StemPoint Capital LP			1.5%	616,749
StemPoint Capital Management GP LLC			1.5%	616,749
Michelle Ross			1.5%	616,749
Surrozen, Inc. 13G/A Amendment 4 SRZN · 86889P208	SRZN	86889P208	7.0%	619,766	13G/A Amendment 4	2/17/2026 Event 12/31/2025
StemPoint Capital LP			7.0%	619,766
StemPoint Capital Management GP LLC			7.0%	619,766
Michelle Ross			7.0%	619,766
Xilio Therapeutics, Inc. 13G/A Amendment 1 XLO · 98422T100	XLO	98422T100	8.4%	6,030,028	13G/A Amendment 1	2/17/2026 Event 12/31/2025
StemPoint Capital LP			8.4%	6,030,028
StemPoint Capital Management GP LLC			8.4%	6,030,028
Michelle Ross			8.4%	6,030,028
Xilio Therapeutics, Inc. 13G XLO · 98422T100	XLO	98422T100	7.2%	4,000,000	13G	11/14/2025 Event 9/30/2025
StemPoint Capital LP			7.2%	4,000,000
StemPoint Capital Management GP LLC			7.2%	4,000,000
Michelle Ross			7.2%	4,000,000
Surrozen, Inc. 13G/A Amendment 3 SRZN · 86889P208	SRZN	86889P208	11.4%	1,016,197	13G/A Amendment 3	8/14/2025 Event 6/30/2025
StemPoint Capital LP			11.4%	1,016,197
StemPoint Capital Management GP LLC			11.4%	1,016,197
Michelle Ross			11.4%	1,016,197
Surrozen, Inc. 13G/A Amendment 2 SRZN · 86889P208	SRZN	86889P208	15.8%	570,484	13G/A Amendment 2	5/15/2025 Event 3/31/2025
StemPoint Capital LP			15.8%	570,484
StemPoint Capital Management GP LLC			15.8%	570,484
Michelle Ross			15.8%	570,484
Surrozen, Inc. 13G/A Amendment 1 SRZN · 86889P208	SRZN	86889P208	14.3%	485,231	13G/A Amendment 1	2/14/2025 Event 12/31/2024
StemPoint Capital LP			14.3%	485,231
StemPoint Capital Management GP LLC			14.3%	485,231
Michelle Ross			14.3%	485,231
Vistagen Therapeutics, Inc 13G/A Amendment 1 VTGN · 92840H400	VTGN	92840H400	8.2%	2,328,492	13G/A Amendment 1	2/14/2025 Event 12/31/2024
StemPoint Capital LP			8.2%	2,328,492
StemPoint Capital Management GP LLC			8.2%	2,328,492
Michelle Ross			8.2%	2,328,492